CR20120127A - Anticuerpos monoclonales - Google Patents

Anticuerpos monoclonales

Info

Publication number
CR20120127A
CR20120127A CR20120127A CR20120127A CR20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A
Authority
CR
Costa Rica
Prior art keywords
monoclonal antibodies
fibrinogen
fibrin
domain
inhibits
Prior art date
Application number
CR20120127A
Other languages
English (en)
Inventor
Katerina Akassoglou
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CR20120127A publication Critical patent/CR20120127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee un anticuerpo aislado que se une al dominio YC de fibrina o fibrinógeno. en varios aspectos, el anticuerpo inhibe la adhesión microglial al dominio YC de fibrina o fibrinógeno, inhibe la unión del Mac-1 al dominio YC de fibrina o fibrinógeno.
CR20120127A 2009-10-02 2012-03-16 Anticuerpos monoclonales CR20120127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24801409P 2009-10-02 2009-10-02

Publications (1)

Publication Number Publication Date
CR20120127A true CR20120127A (es) 2012-05-28

Family

ID=43826649

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120127A CR20120127A (es) 2009-10-02 2012-03-16 Anticuerpos monoclonales

Country Status (38)

Country Link
US (1) US8877195B2 (es)
EP (1) EP2483416B1 (es)
JP (1) JP5883389B2 (es)
KR (1) KR101793221B1 (es)
CN (1) CN102575277B (es)
AR (1) AR078490A1 (es)
AU (1) AU2010300559B2 (es)
BR (1) BR112012008370B8 (es)
CA (1) CA2774256C (es)
CL (1) CL2012000788A1 (es)
CO (1) CO6440561A2 (es)
CR (1) CR20120127A (es)
CY (1) CY1118540T1 (es)
DK (1) DK2483416T3 (es)
DO (1) DOP2012000089A (es)
EA (1) EA023477B1 (es)
ES (1) ES2614939T3 (es)
GE (2) GEP20166458B (es)
GT (1) GT201200096A (es)
HR (1) HRP20170110T1 (es)
HU (1) HUE031571T2 (es)
IL (1) IL218621B (es)
IN (1) IN2012DN03154A (es)
LT (1) LT2483416T (es)
MA (1) MA33704B1 (es)
MX (1) MX2012003811A (es)
MY (1) MY159359A (es)
NZ (1) NZ598770A (es)
PH (1) PH12012500551A1 (es)
PL (1) PL2483416T3 (es)
PT (1) PT2483416T (es)
SI (1) SI2483416T1 (es)
SM (2) SMT201700083T1 (es)
TN (1) TN2012000149A1 (es)
TW (1) TWI511741B (es)
UA (1) UA108860C2 (es)
WO (1) WO2011041518A1 (es)
ZA (1) ZA201202227B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
ES2835716T3 (es) * 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
US10451611B2 (en) 2014-01-11 2019-10-22 The J. David Gladstone Institute Compositions and methods for in vitro assays of fibrin activity
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11311626B2 (en) * 2017-05-02 2022-04-26 National Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
US12600797B2 (en) 2020-03-31 2026-04-14 Rin Institute Inc. Fibrin-binding antibody and pharmaceutical composition containing antibody
WO2022133028A1 (en) * 2020-12-16 2022-06-23 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis
WO2022159776A1 (en) * 2021-01-21 2022-07-28 Therini Bio, Inc. Antibodies which bind human fibrin and methods of use
CA3222880A1 (en) * 2021-06-18 2022-12-22 Jeffrey Stavenhagen Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use
JP2024522237A (ja) * 2021-06-18 2024-06-11 セリーニ バイオ インコーポレイテッド ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
WO2024044583A1 (en) * 2022-08-22 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Human anti-fibrin antibodies and uses thereof
WO2024191900A2 (en) * 2023-03-10 2024-09-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods and compositions for cellular immunotherapy – fib4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) * 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
PL2314621T3 (pl) * 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
US7807645B2 (en) * 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment

Also Published As

Publication number Publication date
HRP20170110T1 (hr) 2017-03-24
CN102575277B (zh) 2015-07-29
PH12012500551A1 (en) 2016-03-11
GT201200096A (es) 2014-12-23
HUE031571T2 (en) 2017-07-28
TN2012000149A1 (en) 2013-09-19
GEP20156214B (en) 2015-01-12
EP2483416A4 (en) 2013-06-26
MY159359A (en) 2016-12-30
JP5883389B2 (ja) 2016-03-15
ZA201202227B (en) 2014-11-26
SI2483416T1 (sl) 2017-06-30
SMT201700083T1 (it) 2017-03-08
IN2012DN03154A (es) 2015-09-18
PT2483416T (pt) 2017-02-14
EA023477B1 (ru) 2016-06-30
EP2483416B1 (en) 2016-11-23
WO2011041518A1 (en) 2011-04-07
CL2012000788A1 (es) 2012-09-14
BR112012008370B1 (pt) 2020-12-22
IL218621A0 (en) 2012-05-31
LT2483416T (lt) 2017-04-25
DOP2012000089A (es) 2012-06-30
DK2483416T3 (en) 2017-02-20
MA33704B1 (fr) 2012-10-01
TW201116298A (en) 2011-05-16
MX2012003811A (es) 2012-05-08
CA2774256C (en) 2019-02-19
AU2010300559B2 (en) 2014-11-27
ES2614939T3 (es) 2017-06-02
UA108860C2 (xx) 2015-06-25
GEP20166458B (en) 2016-04-11
HK1168871A1 (zh) 2013-01-11
CY1118540T1 (el) 2017-07-12
TWI511741B (zh) 2015-12-11
KR101793221B1 (ko) 2017-11-02
AU2010300559A1 (en) 2012-04-05
EA201270416A1 (ru) 2012-08-30
SMT201700083B (it) 2017-03-08
CO6440561A2 (es) 2012-05-15
JP2013506425A (ja) 2013-02-28
NZ598770A (en) 2014-01-31
EP2483416A1 (en) 2012-08-08
CA2774256A1 (en) 2011-04-07
IL218621B (en) 2018-07-31
KR20120094924A (ko) 2012-08-27
AR078490A1 (es) 2011-11-09
US8877195B2 (en) 2014-11-04
PL2483416T3 (pl) 2017-05-31
BR112012008370B8 (pt) 2021-05-25
US20120183560A1 (en) 2012-07-19
CN102575277A (zh) 2012-07-11
BR112012008370A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
ECSP14013307A (es) Genzyme corporation
CO6440561A2 (es) Anticuerpos monoclonales
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CL2011002306A1 (es) Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX373426B (es) Moleculas de enlace a il-18.
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
MX384225B (es) ANTICUERPOS IgG BIESPECIFICOS, ACOPLADORES DE LINFOCITOS T.
CR20110559A (es) Anticuerpos específicos para cadherina-17
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
NZ602294A (en) Monoclonal antibodies against c-met
EA201291065A1 (ru) Антитела против vla-4
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
CY1118420T1 (el) Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
GT201200266A (es) Anticuerpos il-25 humanizados
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы